fibrinogen has been researched along with Activated Protein C Resistance in 21 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (9.52) | 18.2507 |
2000's | 12 (57.14) | 29.6817 |
2010's | 7 (33.33) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Akinci, E; Bodur, H; Dagdas, S; Eren, S; Onguru, P; Ozet, G; Yilmaz, M | 1 |
Baghaei, F; Fagerberg Blixter, I; Gustafsson, KM; Hillarp, A; Lindahl, TL; Sten-Linder, M; Stigendal, L; Strandberg, K | 1 |
Baghaei, F; Blixter, IF; Gustafsson, KM; Hillarp, A; Lindahl, TL; Sten-Linder, M; Stigendal, L; Strandberg, K | 1 |
Bedi, VS; Mishra, MN | 1 |
Duijkers, I; Junge, W; Klipping, C; Mellinger, U; Parke, S; Serrani, M | 1 |
Brenner, B; Klein, E; Makhoul, B; Robicsek, O; Sarig, G | 1 |
Burghardt, S; Giers, G; Handschel, J; Kübler, NR; Naujoks, C | 1 |
De Staercke, C; Hooper, WC | 1 |
Girolami, A; Paternoster, DM; Simioni, P; Snijders, D; Stella, A | 1 |
Bałszan-Kowalska, I; Bińczak-Kuleta, A; Chełstowski, K; Ciechanowicz, A; Falkowski, A; Jastrzebska, M | 1 |
Fijnheer, R; Probst, K; Rothova, A | 1 |
Kapiotis, S; Katzenschlager, R; Miehsler, W; Novacek, G; Speiser, W; Vogelsang, H | 1 |
Kapsoritakis, A; Kouroumalis, EA; Koutroubakis, IE; Maladaki, A; Manousos, ON; Mouzas, IA; Roussomoustakaki, M; Sfiridaki, A | 1 |
Koh, SC; Prasad, RN; Ratnam, SS; Viegas, OA | 1 |
Girolami, A; Patrassi, GM; Sartori, MT; Simioni, P; Theodoridis, P; Tormene, D | 1 |
Anastasopoulou, J; Athanasiou, A; Karafoulidou, A; Kyriakidis, M; Terpos, E; Tsoukala, C | 1 |
Biedermann, T; Flaig, MJ; Sander, CA | 1 |
Ayhan, A; Baykal, C; Demirol, A; Kirazli, S | 1 |
Mannucci, PM; Tripodi, A | 1 |
Lowe, GD; Rumley, A; Rumley, J; Sweetnam, PM; Yarnell, JW | 1 |
Di Micco, B; Di Micco, P; Federico, A; Niglio, A; Nozzolillo, P; Nunziata, L; Petronella, P; Romano, M; Torella, R | 1 |
2 review(s) available for fibrinogen and Activated Protein C Resistance
Article | Year |
---|---|
Venous thromboembolism: implications for gene-based diagnosis and technology development.
Topics: Activated Protein C Resistance; Blood Proteins; Disease Susceptibility; Epistasis, Genetic; Factor V; Female; Fibrinogen; Forecasting; Genetic Predisposition to Disease; Humans; Hyperhomocysteinemia; Male; Molecular Diagnostic Techniques; Neoplasms; Platelet Membrane Glycoproteins; Pregnancy; Pregnancy Complications, Hematologic; Prothrombin; Thromboembolism; Thrombophilia; Venous Thrombosis | 2002 |
Laboratory investigation of thrombophilia.
Topics: Activated Protein C Resistance; Antiphospholipid Syndrome; Antithrombins; Clinical Laboratory Techniques; Coronary Thrombosis; Factor V; Factor VIII; Fibrinogen; Humans; Hyperhomocysteinemia; Mutation; Protein C; Protein S; Prothrombin; Stroke; Thrombophilia; Venous Thrombosis | 2001 |
3 trial(s) available for fibrinogen and Activated Protein C Resistance
Article | Year |
---|---|
Hemostatic effects of a novel estradiol-based oral contraceptive: an open-label, randomized, crossover study of estradiol valerate/dienogest versus ethinylestradiol/levonorgestrel.
Topics: Activated Protein C Resistance; Adolescent; Adult; Antigens; Antithrombin III; Blood Pressure; Contraceptives, Oral, Hormonal; Cross-Over Studies; Drug Combinations; Estradiol; Ethinyl Estradiol; Factor VII; Factor VIII; Female; Fibrin Fibrinogen Degradation Products; Fibrinogen; Hemostasis; Humans; Levonorgestrel; Middle Aged; Nandrolone; Patient Compliance; Peptide Fragments; Protein C; Protein Precursors; Protein S; Prothrombin; Sex Hormone-Binding Globulin; Young Adult | 2011 |
Effects on hemostasis after two-year use of low dose combined oral contraceptives with gestodene or levonorgestrel.
Topics: Activated Protein C Resistance; Adolescent; Adult; Analysis of Variance; Antigens; Antithrombin III; beta-Thromboglobulin; Blood Platelets; Contraceptives, Oral, Synthetic; Factor VII; Female; Fibrin Fibrinogen Degradation Products; Fibrinogen; Hematocrit; Hemoglobins; Hemostasis; Humans; Levonorgestrel; Norpregnenes; Partial Thromboplastin Time; Peptide Fragments; Peptide Hydrolases; Plasminogen; Progesterone Congeners; Protein C; Protein S; Prothrombin; Thrombelastography; Time Factors; Tissue Plasminogen Activator; Urokinase-Type Plasminogen Activator; von Willebrand Factor | 1999 |
Effects of hormone replacement on hemostasis in spontaneous menopause.
Topics: Activated Protein C Resistance; Adult; Antithrombin III; Blood Coagulation Factors; Double-Blind Method; Estrogen Replacement Therapy; Factor IX; Factor VIII; Female; Fibrinogen; Hemostasis; Humans; Lipoprotein(a); Medroxyprogesterone Acetate; Middle Aged; Partial Thromboplastin Time; Placebos; Prothrombin Time | 2001 |
16 other study(ies) available for fibrinogen and Activated Protein C Resistance
Article | Year |
---|---|
Coagulopathy parameters in patients with Crimean-Congo hemorrhagic fever and its relation with mortality.
Topics: Activated Protein C Resistance; Antithrombin III; Blood Coagulation Factors; Blood Coagulation Tests; Female; Fibrin Fibrinogen Degradation Products; Fibrinogen; Hemorrhage; Hemorrhagic Fever, Crimean; Humans; International Normalized Ratio; Male; Partial Thromboplastin Time; Platelet Count; Prognosis; Protein C; Protein S; Prothrombin Time; Risk Factors | 2010 |
Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays.
Topics: Activated Protein C Resistance; Administration, Oral; Adult; Anticoagulants; Antithrombins; Blood Coagulation; Blood Coagulation Tests; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Female; Fibrinogen; Humans; Male; Morpholines; Partial Thromboplastin Time; Predictive Value of Tests; Prothrombin Time; Reproducibility of Results; Rivaroxaban; Thiophenes | 2011 |
Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays.
Topics: Activated Protein C Resistance; Administration, Oral; Adult; Aged; Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation; Blood Coagulation Tests; Dabigatran; Dose-Response Relationship, Drug; Female; Fibrinogen; Humans; Male; Middle Aged; Partial Thromboplastin Time; Prothrombin Time; Reproducibility of Results; Thrombin | 2011 |
Prevalence of common thrombophilia markers and risk factors in Indian patients with primary venous thrombosis.
Topics: Activated Protein C Resistance; Adult; Biomarkers; Epidemiologic Methods; Female; Fibrinogen; Humans; India; Male; Middle Aged; Popliteal Vein; Protein S; Risk Factors; Thrombophilia; Venous Thrombosis; Young Adult | 2010 |
Hypercoagulation in chronic post-traumatic stress disorder.
Topics: Activated Protein C Resistance; Adult; Biomarkers; Blood Coagulation Factors; Chronic Disease; Factor VIII; Fibrin Fibrinogen Degradation Products; Fibrinogen; Humans; Israel; Male; Peptide Fragments; Protein Precursors; Prothrombin; Stress Disorders, Post-Traumatic; Surveys and Questionnaires; Thrombophilia; Thromboplastin; von Willebrand Factor | 2011 |
Parameters predicting complications in flap surgery.
Topics: Activated Protein C Resistance; Blood Coagulation Tests; C-Reactive Protein; Factor VIII; Female; Fibrinogen; Follow-Up Studies; Forecasting; Free Tissue Flaps; Hematologic Tests; Hemorrhagic Disorders; Humans; Male; Necrosis; Plastic Surgery Procedures; Platelet Function Tests; Postoperative Complications; Postoperative Hemorrhage; Prospective Studies; Reoperation; Skin Transplantation; Surgical Flaps; Thrombophilia; Thrombosis; Venous Thrombosis; von Willebrand Factor | 2013 |
Activated protein C resistance in normal and pre-eclamptic pregnancies.
Topics: Activated Protein C Resistance; Adult; Antithrombin III; Case-Control Studies; Factor V; Female; Fibrinogen; Fibronectins; Haptoglobins; Humans; Italy; Partial Thromboplastin Time; Polymerase Chain Reaction; Pre-Eclampsia; Pregnancy; Pregnancy Trimesters; Prenatal Diagnosis; Prevalence; Prospective Studies; Prothrombin Time | 2002 |
[Activated protein C resistance, Leiden mutation, anticoagulant proteins and fibrinogen levels in patients with deep venous thrombosis].
Topics: Activated Protein C Resistance; DNA Primers; Factor V; Female; Fibrinogen; Humans; Male; Middle Aged; Point Mutation; Venous Thrombosis | 2003 |
Endothelial cell activation and hypercoagulability in ocular Behçet's disease.
Topics: Activated Protein C Resistance; Adult; Antigens; Antithrombin III; Behcet Syndrome; Cross-Sectional Studies; Endothelium, Vascular; Factor VIII; Female; Fibrinogen; Humans; Male; Middle Aged; Prospective Studies; Protein C; Protein S; Ristocetin; Thrombophilia; Venous Thrombosis; von Willebrand Factor | 2004 |
Thromboembolism and resistance to activated protein C in patients with inflammatory bowel disease.
Topics: Activated Protein C Resistance; Adolescent; Adult; Aged; Antithrombin III; C-Reactive Protein; Female; Fibrinogen; Humans; Inflammatory Bowel Diseases; Male; Middle Aged; Risk Factors; Thromboembolism | 1999 |
Resistance to activated protein C and low levels of free protein S in Greek patients with inflammatory bowel disease.
Topics: Activated Protein C Resistance; Adult; Antithrombin III; Female; Fibrinogen; Humans; Inflammatory Bowel Diseases; Male; Middle Aged; Protein C; Protein S; Thrombophilia | 2000 |
Combined heterozygous plasminogen deficiency and factor V Leiden defect in the same kindred.
Topics: Activated Protein C Resistance; Adult; Aged; Antibodies, Antiphospholipid; Antithrombins; Factor V; Family Health; Female; Fibrinogen; Fibrinolytic Agents; Genotype; Heterozygote; Humans; Lupus Coagulation Inhibitor; Male; Middle Aged; Partial Thromboplastin Time; Pedigree; Plasminogen; Point Mutation; Protein C; Protein S; Prothrombin; Prothrombin Time | 2000 |
Thrombophilic factors in patients with Syndrome X.
Topics: Activated Protein C Resistance; Antithrombin III; Blood Coagulation Factors; Case-Control Studies; Enzyme-Linked Immunosorbent Assay; Factor VII; Factor VIII; Female; Fibrinogen; Humans; Male; Microvascular Angina; Middle Aged; Plasminogen; Plasminogen Activator Inhibitor 1; Protein C; Protein S; Risk Factors; Thrombosis; Tissue Plasminogen Activator; von Willebrand Factor | 2000 |
Livedoid vasculopathy in a patient with factor V mutation (Leiden).
Topics: Activated Protein C Resistance; Antibodies, Antineutrophil Cytoplasmic; Blood Vessels; Complement C3; DNA; Factor V; Female; Fibrinogen; Fluorescent Antibody Technique, Direct; Humans; Immunoglobulin M; Leg Ulcer; Middle Aged; Point Mutation; Polymerase Chain Reaction; Skin; Skin Diseases, Vascular; Vasculitis | 2000 |
Fibrin D-dimer, markers of coagulation activation and the risk of major ischaemic heart disease in the caerphilly study.
Topics: Activated Protein C Resistance; Antigens; Antithrombin III; Biomarkers; Blood Coagulation; Cohort Studies; Disease Susceptibility; Factor VII; Female; Fibrin Fibrinogen Degradation Products; Fibrinogen; Humans; Incidence; Male; Middle Aged; Myocardial Ischemia; Northern Ireland; Odds Ratio; Partial Thromboplastin Time; Peptide Fragments; Peptide Hydrolases; Predictive Value of Tests; Prothrombin | 2001 |
Alteration of haemostasis in non-metastatic gastric cancer.
Topics: Activated Protein C Resistance; Case-Control Studies; Female; Fibrin Fibrinogen Degradation Products; Fibrinogen; Fibrinolysis; Hemostasis; Humans; Male; Middle Aged; Partial Thromboplastin Time; Prothrombin Time; Stomach Neoplasms; Thrombin; Thromboembolism; Tissue Plasminogen Activator | 2001 |